|
KMID : 0043320180410020162
|
|
Archives of Pharmacal Research
2018 Volume.41 No. 2 p.162 ~ p.183
|
|
|
Therapeutic effects of histone deacetylase inhibitors on kidney disease
|
|
Chun Pu-Soon
|
|
|
Abstract
|
|
|
|
Increasing evidence has shown the involvement of histone deacetylases (HDACs) in the development and progression of various renal diseases, highlighting its inhibition as a promising therapeutic strategy to prevent kidney diseases. Accordingly, numerous studies have shown that HDAC inhibitors protect the kidneys from various diseases through their effects on multiple pathways, such as suppression of transforming growth factor-β signaling pathway and nuclear factor-κB signaling pathways, augmentation of apoptosis, and inhibition of angiogenesis. To develop more effective and less toxic isoform-selective HDAC inhibitors and further improve clinical outcomes, it is necessary to identify and understand the mechanisms involved in the pathogenesis and progression of renal diseases. This review focuses on the roles of HDAC inhibitors and the mechanisms involved in their therapeutic effects in experimental models of kidney diseases including glomerulosclerosis, tubulointerstitial fibrosis, glomerular and tubulointerstitial inflammation, lupus nephritis, polycystic kidney disease, and renal cell carcinoma (RCC).
|
|
|
KEYWORD
|
|
|
Histone deacetylase inhibitors, Fibrosis, Inflammation, Renal cell carcinoma, TGF-β signaling pathway
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|
|